Abstract
Synergy is derived from the Greek word σuvεργóζ meaning working together. In pharmacological terms it has a precise meaning, which is distinct from interaction between two or more active substances where the interaction may be on the absorption, distribution, metabolism or excretion of one or more of the substances. For a synergistic therapeutic effect to occur there need not necessarily be an interaction of this type but the effect should be to the patient’s therapeutic advantage.
Historically, the seeking for the universal panacea or cure for all ills has to some extent hinged on the philosophy of empirical polypharmacy. This can be traced back to philosophies such as that evolved by Mithridates VI, King of Pontus 133 B.C.-63 B.C. (see Griffin 1994). Pontus abounded in medicinal plants and Mithridates acquired considerable knowledge of them. Like every despot of that period he lived in fear of being assassinated by poisoning, in consequence of which he sought the universal antidote to all poisons. Mithridates proceeded along a simple line of reasoning. Having investigated the powers of a number of single ingredients, which he found to be the antidote to various venoms and poisons individually, he evaluated them experimentally on condemned criminals. He then compounded all the effective substances into one antidote hoping thereby to produce universal protection. A daily dose was taken prophylactically to give the immunity he sought.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alberti KGMM, Hockaday TDR (1987) Diabetes mellitus. In: Weatherall DJ, Ledingham JGG, Warrell DA (eds) Oxford textbook of medicine vol 1, 2nd edn. Oxford Medical, Oxford, pp 9.51–9.101
Almond MK, Tailor D, Kelsey SM, Cunningham J (1994) Treatment of erythropoietin resistance with cyclosporin. Lancet 343:916–917
Boulton AJM, Levin S, Comstock J (1990) A multicenter trial of the aldosereductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33:431–437
British National Formulary (1981) No 1. British Medical Association and Royal Pharmaceutical Society of Great Britain, London
British National Formulary (1994) No 27. British Medical Association and Royal Pharmaceutical Society of Great Britain, London
Chadwick D (1993) Seizures, epilepsy and other episodic disorder. In: Walton J (ed) Brain’s diseases of the nervous system, 10th edn. Oxford Medical, Oxford, p 718
Clissold SP, Edwards C (1988) Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214–243
Crounse RG (1961) Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption. J Invest Dermatol 37:529–533
Ginsburg CM, McCracken GH Jr, Petruska M, Olsen K (1983) Effect of feeding on bioavailability of griseofulvin in children. J Pediatr 102:309–311
Green A. Jaspan J (1990) Treatment of diabetic neuropathy with inhibitors of the aldose reductase enzyme. J Diabetic Complications 4:138–144
Griffin JP (1994) Mithridates VI of Pontus, the first experimental toxicologist. Adv Drug React Toxicol Rev 14:1–6
Griffin JR, Wyles M (1991) Epilepsy, towards tomorrow. Office of Health Economics, London
Griffin JP, D’Arcy PF, Speirs CJ (1988) A manual of adverse drug interactions, 4th edn. Wright, (Bulterworth) London
Gustavson LE, Kaiser JF, Mukherjee DX, Schneck DW (1994) Evaluation of the pharmacokinetic drug interactions between clarithromycin and omeprazole (Abstr). 10th World Congress of Gastroenterology, Oct 2–7, Los Angeles
Heberden W (1745) Antitherica, essay on Mithridatium and Theriac. London
Hitchings GH, Elion GB, Vanderwerff H, Falco EA (1948) Pyrimidine derivatives as antagonists of P.G.A. J Biol Chem 174:765–766
Holdiness MR (1989) Clinical pharmacokinetics of clofazimine: a review. Clin Pharmacokinet 16:74–85
Hoskings SW, Ling TKW, Chung S, Yung MY, Cheng AFB (1994) Duodenal ulcer healing by eradication of Helicobacter pylori without anti acid treatment. Lancet 343:508–510
Kirchain W, Rendell M (1990) Aldose reductase inhibitors. Pharmacotherapy 10:326–336
Knatterud GL, Meinert CL, Klimt C, Osborne RK, Martin DB (1971) Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. IV. A preliminary report on phenformin results. JAMA 217:777–784
Lasseter KC, Levey GS, Palmer RF, McCarthy JS (1972) The effects of sulfonylurea drugs on rabbit myocardial contractility, canine Purkinje fiber automaticity, and adenylcyclase activity from rabbit and human hearts. J Clin Invest 5:2429–2432
Logan RPH (1994) Clarithromycin may prevent ulcer recurrence. 7th Workshop on Gastroduodenal Pathology and Helicobacter pylori, Sept 30, Houston
Masson EA, Boulton AJM (1990) Aldose reductase inhibitors in the treatment of diabetic neuropathy: a review of the rationale and clinical evidence. Drugs 39:190–202
Medicines Resource Centre (1994) Combination diuretics. MeRec Bull 5(10)
Melander A, Danielson K, Schersten B, Wahlin E (1977) Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 22:108–112
New Medicines (1994) Acarbose — an α-glucosidase inhibitor. Int Pharm J 8:11–12
Prout TE (1975) A progress report on the University Group Diabetes Program. Int J Clin Pharmacol 12:244–251
Reynolds JEF (ed) (1993) Martindale, the extra pharmacopoeia. Pharmaceutical Press, London, pp 137–138, 151–152
Ridgway E, Stewart K, Rai G, Kelsey MC, Bielawska C (1991) The pharmacokinetics of cefuroxim axetil in the sick elderly patient. J Antimicrob Chemother 27:663–668
Rosenberg HA, Bates TR (1976) The influence of food on nitrofurantoin bioavailability. Clin Pharmacol Ther 20:227–232
Sales JEL, Sutcliffe M, O’Grady F (1972) Cephalexin levels in human bile in presence of biliary tract disease. Br Med J 3:441–443
Shanks RG (1979) Cardiac dysfunction. In: D’Arcy PF, Griffin JP (eds) Iatrogenic diseases, 2nd edn, Oxford Medical, Oxford, pp 116–131
Sneader W (1985) Drug discovery: the evolution of modern medicines. Wiley, Chichester
Soler NG, Pentecost BL, Bennett MA, Fitzgerald MG, Lamb P, Malins JM (1974) Coronary care for myocardial infarction in diabetes. Lancet I:457–477
Tsai SC, Burnakis TG (1993) Aldose reductase inhibitors: an update. Ann Pharmacother 27:751–754
University Group Diabetes Program (1970) A study of the effects of hyperglycemic agents on vascular complications in patients with adult onset diabetes. II. Mortality results. Diabetes 19 [Suppl]: 789–830
Van Gerven J, Lemkes H, van Dijk J (1992) Long-term effects of tolrestat in symptomatic diabetic sensory polyneuropathy. J Diabetes Complications 6:45–48
Van Peer A, Westenborghs R, Heykants J, Gasparini R, Gauwenbergh G (1989) The effect of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 36:423–426
Zenon G, Abobo C, Carter B, Ball D (1990) Potential use of aldose reductase inhibitors to prevent diabetic complications. Clin Pharm 9:446–457
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Griffin, J.P., D’Arcy, P.F. (1996). Synergistic Drug Interactions. In: D’Arcy, P.F., McElnay, J.C., Welling, P.G. (eds) Mechanisms of Drug Interactions. Handbook of Experimental Pharmacology, vol 122. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61015-8_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-61015-8_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64658-4
Online ISBN: 978-3-642-61015-8
eBook Packages: Springer Book Archive